Evidence map›Paper›PMID 35776566›Full record

ReviewThe British journal of radiology2023

Non-oncologic incidental uptake on FAPI PET/CT imaging.

Masatoshi Hotta, Angela C Rieger, Mahbod G Jafarvand, Nandakumar Menon, Andrea Farolfi, Matthias R Benz, Jeremie Calais

Open access · bronzeAbstract readReview
In one paragraph

Review in The British journal of radiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed, 1 pooled it
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 1 synthesis or guideline pooled it, 86 citations in OpenAlex.

  1. Pooled it
  2. Correlation of FAPI PET Uptake with Immunohistochemistry in Explanted Lungs from Patients with Advanced Interstitial Lung Disease.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2024
    Trial
  3. Article
  4. First-in-human EphA2-targeting PET imaging with the bicyclic radiotracer [European journal of nuclear medicine and molecular imaging · 2026
    Article
  5. Article
  6. European journal of nuclear medicine and molecular imaging · 2026
    Article
  7. Article
  8. FAP-targeted [European journal of nuclear medicine and molecular imaging · 2026
    Article
  9. Review
  10. Review
  11. European journal of nuclear medicine and molecular imaging · 2026
    Article
  12. Diagnostic Efficacy of FAPI-PET/CT Versus [Diagnostics (Basel, Switzerland) · 2026
    Review
  13. Digital Biopsy and Network Analysis of Dynamic [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  14. Review
  15. Review
  16. [European journal of nuclear medicine and molecular imaging · 2026
    Article
  17. [EJNMMI research · 2025
    Article
  18. Head-to-head comparison ofEuropean journal of nuclear medicine and molecular imaging · 2025
    Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Masatoshi HottaAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California, Los Angeles, USA.ORCID 0000-0001-6790-8804
Angela C RiegerAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California, Los Angeles, USA.
Mahbod G JafarvandAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California, Los Angeles, USA.
Nandakumar MenonAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California, Los Angeles, USA.
Andrea FarolfiAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California, Los Angeles, USA.
Matthias R BenzAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California, Los Angeles, USA.
Jeremie CalaisAhmanson Translational Theranostics Division, Department of Molecular & Medical Pharmacology, University of California, Los Angeles, USA.
University of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fibroblast-activation protein (FAP) is a serine protease classified in the dipeptidyl peptidase 4 (DPP4) family. FAP is predominantly expressed in activated fibroblasts such as the cancer-associated fibroblasts (CAFs). FAP expression in CAFs is associated with tumor progression and poor prognosis in solid cancers. Recently, radiolabeled FAP inhibitors (FAPI) has been developed, which enables positron emission tomography (PET) imaging of FAP. FAPI PET/CT can provide a higher tumor-to-background ratio (TBR) than

Indexed as

Positron-Emission TomographyPositron Emission Tomography Computed TomographyBiological TransportGallium RadioisotopesHumansKidneyLiverGallium Radioisotopes

Identifiers

PMID35776566
PMCPMC9975522
OpenAlexW4283742960

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.